Details of the Drug

General Information of Drug (ID: DMIBH7M)

• Drug Name: L-Tryptophan
• Synonyms: Ardeytropin; Kalma; LTR; Lyphan; Optimax; Pacitron; Sedanoct; Triptofano; Trofan; Trp; Tryptacin; Tryptan; Tryptophane; Tryptophanum; Triptofano [Spanish]; Tryptophane [French]; Tryptophanum [Latin]; EH 121; MT1; T 0254; Alti-Tryptophan; L-TRYPTOPHAN SIGMA GRADE; L-Trp; L-Tryptofan; L-Tryptophane; L-Ttp; TRP NH3+ COOH; TRP-01; Tryptophan (VAN); Tryptophan [USAN:INN]; H-Trp-oh; Indole-3-alanine; L-Tryptophan (9CI); L-Tryptophan (JP15); Tryptophan (H-3); Tryptophan (USP/INN); L-b-3-Indolylalanine; L-beta-3-Indolylalanine; Tryptophan, L-(8CI); Alanine, 3-indol-3-yl; Alpha'-Amino-3-indolepropionic acid; L-(-)-Tryptophan; L-(-)-Tryptophane; L-a-Aminoindole-3-propionic acid; L-alpha-Aminoindole-3-propionic acid; L-alpha-amino-3-indolepropionic acid; Alpha-Amino-beta-(3-indolyl)-propionic acid; Alpha-amino-beta-(3-indolyl)-pr opionic acid; Propionic acid, 2-amino-3-indol-3-yl; S(-)-1-alpha-Aminoindole-3-propionic acid; (2S)-2-amino-3-(1H-indol-3-yl)propanoic acid; (L)-TRYPTOPHAN; (S)-(-)-2-Amino-3-(3-indolyl)propionic Acid; (S)-(-)-Tryptopha n; (S)-(-)-Tryptophan; (S)-2-Amino-3-(1H-indol-3-yl)propanoic acid; (S)-2-Amino-3-(3-indolyl)propionic acid; (S)-Tryptophan; (S)-a-Amino-1H-indole-3-propanoic acid; (S)-a-Amino-b-indolepropionic acid; (S)-a-Aminoindole-3-propionic acid; (S)-alpha-Amino-1H-indole-3-propanoic acid; (S)-alpha-Amino-beta-indolepropionic acid; (S)-alpha-Aminoindole-3-propionic acid; (S)-alpha-amino-beta-(3-indolyl)-propionic acid; 1-beta-3-Indolylalanine; 151A3008-4CFE-40C9-AC0B-467EF0CB50EA; 1H-Indole-3-alanine; 1H-Indole-3-alanine (VAN); 1beta-3-Indolylalanine; 2-Amino-3-(lH-indol-3-yl)-propanoic acid; 2-Amino-3-indolylpropanoic acid; 2-amino-3-indol-3-ylpropionic acid; 3-Indol-3-ylalanine

Indication

Disease Entry	ICD 11	Status	REF
Depression	6A70-6A7Z	Approved	[1]

• Therapeutic Class: Antidepressants
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 204.22
  Logarithm of the Partition Coefficient (xlogp); -1.1
  Rotatable Bond Count (rotbonds); 3
  Hydrogen Bond Donor Count (hbonddonor); 3
  Hydrogen Bond Acceptor Count (hbondacc); 3
• ADMET Property: Metabolism: The drug is metabolized via the hepatic []
• Chemical Identifiers:
  Formula: C11H12N2O2
  IUPAC Name: (2S)-2-amino-3-(1H-indol-3-yl)propanoic acid
  Canonical SMILES: C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)N
  InChI: InChI=1S/C11H12N2O2/c12-9(11(14)15)5-7-6-13-10-4-2-1-3-8(7)10/h1-4,6,9,13H,5,12H2,(H,14,15)/t9-/m0/s1
  InChIKey: QIVBCDIJIAJPQS-VIFPVBQESA-N
• Cross-matching ID:
  PubChem CID: 6305
  ChEBI ID: CHEBI:16828
  CAS Number: 73-22-3
  DrugBank ID: DB00150
  TTD ID: D05EJG
  VARIDT ID: DR00086
  INTEDE ID: DR0991

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Indoleamine 2,3-dioxygenase 1 (IDO1)	TTZJYKH	I23O1_HUMAN	Binder	[2]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Monocarboxylate transporter 10 (SLC16A10)	DTPAQJO	MOT10_HUMAN	Substrate	[3]
Proton-coupled amino acid transporter 4 (SLC36A4)	DTBS49U	S36A4_HUMAN	Substrate	[4]
L-type amino acid transporter 2 (SLC7A8)	DTJF3DX	LAT2_HUMAN	Substrate	[5]
Organic anion transporter 3 (SLC22A8)	DTVP67E	S22A8_HUMAN	Substrate	[6]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[7]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
DOPA decarboxylase (DDC)	DETK9CN	DDC_HUMAN	Substrate	[8]
Tryptophan oxygenase (TRPO)	DEGH1QU	T23O_HUMAN	Substrate	[9]
Indoleamine 2,3-dioxygenase 1 (IDO1)	DE43MW5	I23O1_HUMAN	Substrate	[10]
Tryptophanyl-tRNA synthetase mitochondrial (WARS2)	DEPTKBQ	SYWM_HUMAN	Substrate	[11]
Tryptophan 5-hydroxylase 1 (TPH1)	DEP5BDK	TPH1_HUMAN	Substrate	[12]
Tryptophanyl-tRNA synthetase cytoplasmic (WARS1)	DEPVE0M	SYWC_HUMAN	Substrate	[13]
Tryptophan 5-hydroxylase 2 (TPH2)	DER6XYF	TPH2_HUMAN	Substrate	[14]
Indoleamine 2,3-dioxygenase 2 (IDO2)	DE8BVKA	I23O2_HUMAN	Substrate	[10]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Aryl hydrocarbon receptor (AHR)	OTFE4EYE	AHR_HUMAN	Gene/Protein Processing	[15]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Gene/Protein Processing	[15]
Cytochrome P450 1B1 (CYP1B1)	OTYXFLSD	CP1B1_HUMAN	Gene/Protein Processing	[15]
Indoleamine 2,3-dioxygenase 1 (IDO1)	OT91DBN7	I23O1_HUMAN	Gene/Protein Processing	[15]
Insulin-like growth factor-binding protein 1 (IGFBP1)	OT6UQV2K	IBP1_HUMAN	Gene/Protein Processing	[15]
Large neutral amino acids transporter small subunit 1 (SLC7A5)	OT2WPVXD	LAT1_HUMAN	Gene/Protein Processing	[15]
Prolactin (PRL)	OTWFQGX7	PRL_HUMAN	Gene/Protein Processing	[15]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as L-Tryptophan

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Sertraline	DM0FB1J	Major	Additive serotonergic effects by the combination of L-tryptophan and Sertraline.	Depression [6A70-6A7Z]	[16]
Cyclobenzaprine	DM1YBRM	Major	Additive serotonergic effects by the combination of L-tryptophan and Cyclobenzaprine.	Depression [6A70-6A7Z]	[17]
Imipramine	DM2NUH3	Major	Additive serotonergic effects by the combination of L-tryptophan and Imipramine.	Depression [6A70-6A7Z]	[17]
Fluoxetine	DM3PD2C	Major	Additive serotonergic effects by the combination of L-tryptophan and Fluoxetine.	Depression [6A70-6A7Z]	[16]
Nortriptyline	DM4KDYJ	Major	Additive serotonergic effects by the combination of L-tryptophan and Nortriptyline.	Depression [6A70-6A7Z]	[17]
Nefazodone	DM4ZS8M	Major	Additive serotonergic effects by the combination of L-tryptophan and Nefazodone.	Depression [6A70-6A7Z]	[17]
Paroxetine	DM5PVQE	Major	Additive serotonergic effects by the combination of L-tryptophan and Paroxetine.	Depression [6A70-6A7Z]	[16]
Selegiline	DM6034S	Major	Additive serotonergic effects by the combination of L-tryptophan and Selegiline.	Depression [6A70-6A7Z]	[18]
Vortioxetine	DM6F1PU	Major	Additive serotonergic effects by the combination of L-tryptophan and Vortioxetine.	Depression [6A70-6A7Z]	[16]
Duloxetine	DM9BI7M	Major	Additive serotonergic effects by the combination of L-tryptophan and Duloxetine.	Depression [6A70-6A7Z]	[16]
Isocarboxazid	DMAF1NB	Major	Additive serotonergic effects by the combination of L-tryptophan and Isocarboxazid.	Depression [6A70-6A7Z]	[18]
Milnacipran	DMBFE74	Major	Additive serotonergic effects by the combination of L-tryptophan and Milnacipran.	Depression [6A70-6A7Z]	[17]
Escitalopram	DMFK9HG	Major	Additive serotonergic effects by the combination of L-tryptophan and Escitalopram.	Depression [6A70-6A7Z]	[16]
Tranylcypromine	DMGB5RE	Major	Additive serotonergic effects by the combination of L-tryptophan and Tranylcypromine.	Depression [6A70-6A7Z]	[18]
Desvenlafaxine	DMHD4PE	Major	Additive serotonergic effects by the combination of L-tryptophan and Desvenlafaxine.	Depression [6A70-6A7Z]	[16]
Phenelzine	DMHIDUE	Major	Additive serotonergic effects by the combination of L-tryptophan and Phenelzine.	Depression [6A70-6A7Z]	[18]
Clomipramine	DMINRKW	Major	Additive serotonergic effects by the combination of L-tryptophan and Clomipramine.	Depression [6A70-6A7Z]	[17]
Trazodone	DMK1GBJ	Major	Additive serotonergic effects by the combination of L-tryptophan and Trazodone.	Depression [6A70-6A7Z]	[17]
Amitriptyline	DMK7F9S	Major	Additive serotonergic effects by the combination of L-tryptophan and Amitriptyline.	Depression [6A70-6A7Z]	[17]
Amoxapine	DMKITQE	Major	Additive serotonergic effects by the combination of L-tryptophan and Amoxapine.	Depression [6A70-6A7Z]	[17]
Mirtazapine	DML53ZJ	Major	Additive serotonergic effects by the combination of L-tryptophan and Mirtazapine.	Depression [6A70-6A7Z]	[17]
Protriptyline	DMNHTZI	Major	Additive serotonergic effects by the combination of L-tryptophan and Protriptyline.	Depression [6A70-6A7Z]	[17]
Doxepin	DMPI98T	Major	Additive serotonergic effects by the combination of L-tryptophan and Doxepin.	Depression [6A70-6A7Z]	[17]
Maprotiline	DMPWB7T	Major	Additive serotonergic effects by the combination of L-tryptophan and Maprotiline.	Depression [6A70-6A7Z]	[17]
Fluvoxamine	DMQTJSX	Major	Additive serotonergic effects by the combination of L-tryptophan and Fluvoxamine.	Depression [6A70-6A7Z]	[16]

Coadministration of a Drug Treating the Disease Different from L-Tryptophan (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Major	Additive serotonergic effects by the combination of L-tryptophan and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[18]
Oliceridine	DM6MDCF	Moderate	Additive serotonergic effects by the combination of L-tryptophan and Oliceridine.	Acute pain [MG31]	[19]
Buspirone	DMBS632	Major	Additive serotonergic effects by the combination of L-tryptophan and Buspirone.	Anxiety disorder [6B00-6B0Z]	[17]
Desipramine	DMT2FDC	Major	Additive serotonergic effects by the combination of L-tryptophan and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[17]
Linezolid	DMGFPU2	Major	Additive serotonergic effects by the combination of L-tryptophan and Linezolid.	Bacterial infection [1A00-1C4Z]	[17]
Dihydrocodeine	DMB0FWL	Moderate	Additive serotonergic effects by the combination of L-tryptophan and Dihydrocodeine.	Chronic pain [MG30]	[19]
Morphine	DMRMS0L	Moderate	Additive CNS depression effects by the combination of L-tryptophan and Morphine.	Chronic pain [MG30]	[19]
Levomilnacipran	DMV26S8	Major	Additive serotonergic effects by the combination of L-tryptophan and Levomilnacipran.	Chronic pain [MG30]	[16]
Methadone	DMTW6IU	Moderate	Additive serotonergic effects by the combination of L-tryptophan and Methadone.	Cough [MD12]	[19]
Citalopram derivative 1	DMITX1G	Major	Additive serotonergic effects by the combination of L-tryptophan and Citalopram derivative 1.	Discovery agent [N.A.]	[16]
Fenfluramine	DM0762O	Major	Additive serotonergic effects by the combination of L-tryptophan and Fenfluramine.	Epilepsy/seizure [8A61-8A6Z]	[16]
Procarbazine	DMIK367	Major	Additive serotonergic effects by the combination of L-tryptophan and Procarbazine.	Hodgkin lymphoma [2B30]	[18]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of L-tryptophan and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[20]
Dihydroergotamine	DM5IKUF	Major	Additive serotonergic effects by the combination of L-tryptophan and Dihydroergotamine.	Migraine [8A80]	[17]
Ozanimod	DMT6AM2	Moderate	Additive serotonergic effects by the combination of L-tryptophan and Ozanimod.	Multiple sclerosis [8A40]	[18]
Palonosetron	DMBHMOX	Major	Additive serotonergic effects by the combination of L-tryptophan and Palonosetron.	Nausea/vomiting [MD90]	[21]
Granisetron	DMIUW25	Major	Additive serotonergic effects by the combination of L-tryptophan and Granisetron.	Nausea/vomiting [MD90]	[21]
Dolasetron	DMMG26Z	Major	Additive serotonergic effects by the combination of L-tryptophan and Dolasetron.	Nausea/vomiting [MD90]	[21]
Ondansetron	DMOTQ1I	Major	Additive serotonergic effects by the combination of L-tryptophan and Ondansetron.	Nausea/vomiting [MD90]	[21]
Sibutramine	DMFJTDI	Major	Additive serotonergic effects by the combination of L-tryptophan and Sibutramine.	Obesity [5B80-5B81]	[22]
Lorcaserin	DMG6OYJ	Major	Additive serotonergic effects by the combination of L-tryptophan and Lorcaserin.	Obesity [5B80-5B81]	[23]
Butorphanol	DM5KYPJ	Moderate	Additive serotonergic effects by the combination of L-tryptophan and Butorphanol.	Pain [MG30-MG3Z]	[19]
Oxymorphone	DM65AGJ	Moderate	Additive serotonergic effects by the combination of L-tryptophan and Oxymorphone.	Pain [MG30-MG3Z]	[19]
Levorphanol	DMGS80V	Moderate	Additive serotonergic effects by the combination of L-tryptophan and Levorphanol.	Pain [MG30-MG3Z]	[19]
Hydromorphone	DMHP21E	Moderate	Additive serotonergic effects by the combination of L-tryptophan and Hydromorphone.	Pain [MG30-MG3Z]	[19]
Codeine	DMJX6ZG	Moderate	Additive serotonergic effects by the combination of L-tryptophan and Codeine.	Pain [MG30-MG3Z]	[19]
Nalbuphine	DMOSQGU	Moderate	Additive serotonergic effects by the combination of L-tryptophan and Nalbuphine.	Pain [MG30-MG3Z]	[19]
Buprenorphine	DMPRI8G	Moderate	Additive serotonergic effects by the combination of L-tryptophan and Buprenorphine.	Pain [MG30-MG3Z]	[19]
Hydrocodone	DMQ2JO5	Moderate	Additive serotonergic effects by the combination of L-tryptophan and Hydrocodone.	Pain [MG30-MG3Z]	[19]
Tramadol	DMRQD04	Major	Additive serotonergic effects by the combination of L-tryptophan and Tramadol.	Pain [MG30-MG3Z]	[17]
Oxycodone	DMXLKHV	Moderate	Additive serotonergic effects by the combination of L-tryptophan and Oxycodone.	Pain [MG30-MG3Z]	[19]
Safinamide	DM0YWJC	Major	Additive serotonergic effects by the combination of L-tryptophan and Safinamide.	Parkinsonism [8A00]	[18]
Rasagiline	DM3WKQ4	Major	Additive serotonergic effects by the combination of L-tryptophan and Rasagiline.	Parkinsonism [8A00]	[18]
Fentanyl	DM8WAHT	Major	Additive serotonergic effects by the combination of L-tryptophan and Fentanyl.	Sensation disturbance [MB40]	[17]
Tizanidine	DMR2IQ4	Moderate	Additive CNS depression effects by the combination of L-tryptophan and Tizanidine.	Tonus and reflex abnormality [MB47]	[24]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 717).
• [2] Interactions between nitric oxide and indoleamine 2,3-dioxygenase. Biochemistry. 2006 Jul 18;45(28):8527-38.
• [3] Phosphatidylserine synthesis required for the maximal tryptophan transport activity in Saccharomyces cerevisiae. Biosci Biotechnol Biochem. 2000 Jan;64(1):167-72.
• [4] SLC36A4 (hPAT4) is a high affinity amino acid transporter when expressed in Xenopus laevis oocytes. J Biol Chem. 2011 Jan 28;286(4):2455-60.
• [5] The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.3.8.20)
• [6] Murine renal organic anion transporters mOAT1 and mOAT3 facilitate the transport of neuroactive tryptophan metabolites. Am J Physiol Cell Physiol. 2005 Nov;289(5):C1075-84.
• [7] Pharmacogenetics of antidepressants. Front Pharmacol. 2011 Feb 16;2:6.
• [8] Origin and metabolism of serotonin. J Cardiovasc Pharmacol. 1990;16 Suppl 3:S1-7.
• [9] Reaction pathway of tryptophanase-catalyzed L-tryptophan synthesis from D-serine. J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Nov 1;879(29):3289-95.
• [10] Kynurenine pathway metabolites and enzymes involved in redox reactions. Neuropharmacology. 2017 Jan;112(Pt B):331-345.
• [11] Crystal structure of tryptophanyl-tRNA synthetase complexed with adenosine-5' tetraphosphate: evidence for distributed use of catalytic binding energy in amino acid activation by class I aminoacyl-tRNA synthetases. J Mol Biol. 2007 May 25;369(1):108-28.
• [12] Developmental role of tryptophan hydroxylase in the nervous system. Mol Neurobiol. 2007 Feb;35(1):45-54.
• [13] IFN-gamma-induced IDO and WRS expression in microglia is differentially regulated by IL-4. Glia. 2007 Oct;55(13):1385-96.
• [14] Strain differences in basal and post-citalopram extracellular 5-HT in the mouse medial prefrontal cortex and dorsal hippocampus: relation with tryptophan hydroxylase-2 activity. J Neurochem. 2007 Nov;103(3):1111-20.
• [15] Tryptophan and kynurenine stimulate human decidualization via activating Aryl hydrocarbon receptor: Short title: Kynurenine action on human decidualization. Reprod Toxicol. 2020 Sep;96:282-292. doi: 10.1016/j.reprotox.2020.07.011. Epub 2020 Aug 8.
• [16] Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL.
• [17] Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
• [18] Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
• [19] Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
• [20] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [21] Canadian Pharmacists Association.
• [22] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
• [23] Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
• [24] Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.